相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report
James Forryan et al.
JOURNAL OF MEDICAL CASE REPORTS (2020)
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML
Doriana Landi et al.
NEUROLOGY (2017)
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Mathias Lutz et al.
CANCER RESEARCH AND TREATMENT (2017)
Classifying PML risk with disease modifying therapies
Joseph R. Berger
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab
Z. Calic et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation
Hitoshi Yoshida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
Stefanie Dahlhaus et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
Progressive multifocal leukoencephalopathy and other forms of JC virus disease
Bruce J. Brew et al.
NATURE REVIEWS NEUROLOGY (2010)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi et al.
BLOOD (2007)
分享论文
